IPO

After a strategic pivot reverses a year of decline, Allurion's preliminary results show new growth. All eyes are now on the FDA for its 'procedureless' gastric balloon.

The genomics leader posted a 41% revenue surge in 2025 and projects profitability, yet its stock tumbled on what some see as conservative 2026 guidance.

V2X secures a major contract under the MDA's SHIELD program, positioning it to shape the future of America's layered defense with advanced tech.

With a key FDA filing and pivotal data on the horizon, Pharvaris aims to redefine HAE treatment with its convenient, rapid-acting oral therapy.

The burger chain posted positive sales and aggressive 2026 growth plans, navigating weather woes and inflation with new menu items and operational tweaks.

Amidst a strategic push for profitability, CytoSorbents advances its DrugSorb-ATR device, aiming to revolutionize safety in cardiac surgery.

Vallourec's significant contract win for Shell's Orca project signals the enduring strategic value of Brazil's deepwater reserves and advanced tech.

A minor change in Collective Metals' $1.5M financing deal reveals the high stakes in its hunt for Canadian uranium. Here’s what it means for investors.

Facing a Nasdaq delisting notice, social commerce firm Webuy Global has 45 days to devise a plan to fix its $2.1M stockholders' equity deficiency.

Hong Kong's 3E Network completes a $2M financing round, fueling its strategic shift into the competitive global AI infrastructure market.

As Triumph Financial preps its Q4 2025 results, investors watch to see if its tech investments can deliver on high growth expectations amid a complex freight market.

The Chinese auto-tech firm regained Nasdaq's minimum bid price but still faces delisting over its low market value, setting up a critical hearing.

VCI Global's new Kuala Lumpur AI Lounge offers subscription access to NVIDIA's top GPUs, aiming to democratize AI and build a future of robotics.

Nasdaq-listed retailer iPower diversifies its balance sheet with Bitcoin and Ethereum, leveraging BitGo's regulated infrastructure for custody and trading.

Biotech firm Bright Minds Biosciences closes a massive $175M deal, fueling its race to develop novel drugs for epilepsy and rare neurological conditions.

The man who scaled Netflix and Spotify joins Strava's board, signaling a major push towards monetization and a potential IPO for the fitness giant.

Gartner recognizes Jamf as a Leader in endpoint management, highlighting the growing dominance of specialized, Apple-centric solutions in the enterprise.

The value furniture giant is going public, revealing strong growth and ambitious expansion plans. Can its "Everyday Low Prices" model win over Wall Street?

Rubico Inc.'s new $4 million offering sent its stock tumbling amid severe dilution concerns and red flags over its financial health and ability to fund growth.

After a year of scrutiny, a former Urban League leader invests in the aspiring minority-controlled stock exchange, validating its mission for structural change.